Physician profile
Ravi Pachigolla
NPI 1396731402
$8,523.83
in general payments reported to CMS, 2019-2025
26 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,241 · 2020: $1,908 · 2021: $1,160 · 2022: $1,543 · 2023: $1,035 · 2024: $895 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119 · Consulting Fee: $400 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.92 |
| Consulting Fee | $400.00 |
| Education | $152.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $2,053.82 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,536.25 | 2019-2025 | Breztri, Farxiga, Tezspire |
| Novo Nordisk INC | $1,029.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Medical Device Business Services, INC. | $978.06 | 2022 | |
| Amgen INC. | $548.98 | 2020-2025 | Repatha, Evenity |
| Regeneron Healthcare Solutions, INC. | $459.48 | 2021-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.51 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $271.30 | 2019-2024 | |
| Acclarent, INC | $216.49 | 2019-2023 | Relieva Spinplus |
| Genzyme Corporation | $164.18 | 2020-2025 | |
| Genentech USA, INC. | $144.10 | 2019-2025 | Xolair |
| Lilly USA, LLC | $135.65 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $118.38 | 2019-2025 | Keytruda, Belsomra |
| Stryker Corporation | $115.30 | 2019-2025 | Xpress Loprofile |
| Lundbeck LLC | $80.80 | 2023-2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $67.18 | 2020-2025 | Tula, Halo |
| Kaleo, INC. | $59.81 | 2021-2024 | Auvi-Q |
| Optinose US, INC. | $44.97 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $44.06 | 2025 | Neffy |
| Otsuka America Pharmaceutical, INC. | $43.60 | 2020-2021 | |
| Integra Lifesciences Corporation | $35.61 | 2023-2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Glaxosmithkline, LLC. | $28.99 | 2021-2025 | Nucala |
| Uswm, LLC | $20.00 | 2021 | |
| Agios Pharmaceuticals, INC. | $19.68 | 2025 | Pyrukynd |
| Forte Bio-Pharma LLC | $18.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Pachigolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.